دورية أكاديمية
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors
| العنوان: | An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors |
|---|---|
| المؤلفون: | Onali S., Pugliese D., Caprioli F. A., Orlando A., Biancone L., Nardone O. M., Imperatore N., Fiorino G., Cappello M., Viola A., Principi M. B., Bezzio C., Aratari A., Carparelli S., Mazzuoli S., Manguso F., Grossi L., Bodini G., Ribaldone D., Mocci G., Miranda A., Minerba L., Favale A., Grova M., Scucchi L., Segato S., Fries W., Castiglione F., Armuzzi A., Fantini M. C. |
| المساهمون: | Onali S., Pugliese D., Caprioli F.A., Orlando A., Biancone L., Nardone O.M., Imperatore N., Fiorino G., Cappello M., Viola A., Principi M.B., Bezzio C., Aratari A., Carparelli S., Mazzuoli S., Manguso F., Grossi L., Bodini G., Ribaldone D., Mocci G., Miranda A., Minerba L., Favale A., Grova M., Scucchi L., Segato S., Fries W., Castiglione F., Armuzzi A., Fantini M.C. |
| سنة النشر: | 2022 |
| المجموعة: | Università degli studi di Torino: AperTo (Archivio Istituzionale ad Accesso Aperto) |
| مصطلحات موضوعية: | Human, Remission Induction, Retrospective Studie, Treatment Outcome, Tumor Necrosis Factor Inhibitor, Antibodies, Monoclonal, Humanized, Crohn Disease, Ustekinumab |
| الوصف: | INTRODUCTION: The use of ustekinumab and vedolizumab as second-line therapies in patients with Crohn's disease (CD) in which tumour necrosis factor alpha inhibitors (TNFi) failed is still debated. The aim of this study was to compare, in a large multicenter observational retrospective cohort, the effectiveness of ustekinumab and vedolizumab as second-line therapies, as assessed by clinical and objective outcomes including endoscopy and gastrointestinal imaging. METHODS: Clinical response, remission, and steroid-free remission at weeks 26 and 52 were evaluated in a retrospective propensity score-weighted and propensity score-matched cohort of patients in which TNFi failed. Objective response and remission were evaluated by 1 or more techniques among endoscopy, magnetic resonance/computed tomography enteroclysis, and small bowel ultrasound. RESULTS: A total of 470 patients with CD (239 treated with ustekinumab and 231 treated with vedolizumab) were included in the study. At week 26, clinical outcomes were similar between the 2 groups. At week 52, clinical remission (ustekinumab 42.5% vs vedolizumab 55.5%, P = 0.01) and steroid-free remission (ustekinumab 40.6% vs vedolizumab 51.1%, P = 0.038) rates were significantly higher in vedolizumab-treated patients. Three hundred two patients (hundred thirty-five treated with ustekinumab and hundred sixty-seven treated with vedolizumab) had an objective evaluation of disease activity at baseline and week 52. At week 52, objective response and remission rates were similar between the 2 groups. Clinical response at week 26 predicted steroid-free remission at week 52 in both ustekinumab-treated and vedolizumab-treated patients. Safety profiles were similar between the 2 groups. DISCUSSION: In patients with CD in which TNFi failed, both ustekinumab and vedolizumab showed similar clinical effectiveness after 26 weeks of treatment. At 1 year, vedolizumab was associated with a higher rate of clinical remission when compared with ustekinumab. However, no difference was observed ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/35467558; info:eu-repo/semantics/altIdentifier/wos/WOS:000835887700023; volume:117; issue:8; firstpage:1279; lastpage:1287; numberofpages:9; journal:THE AMERICAN JOURNAL OF GASTROENTEROLOGY; http://hdl.handle.net/2318/1872619Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85135597946 |
| DOI: | 10.14309/ajg.0000000000001773 |
| الإتاحة: | https://doi.org/10.14309/ajg.0000000000001773Test http://hdl.handle.net/2318/1872619Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.18961F33 |
| قاعدة البيانات: | BASE |
| DOI: | 10.14309/ajg.0000000000001773 |
|---|